Survival of patients with transformed lymphoma in the rituximab era

Annals of Hematology

Volumn 93, Issue 6, 2014, Pages 1007-1014

  Guirguis, Hany R ^a   Cheung, Matthew C ^a   Piliotis, Eugenia ^a   Spaner, David ^a   Berinstein, Neil L ^a   Imrie, Kevin ^a   Zhang, Liying ^a   Buckstein, Rena ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diffuse large B cell lymphoma; R CHOP; Rituximab; Survival; Transformed lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRANSFORMED LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84902330406     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1991-y     Document Type: Article

References (25)

1. Montoto S, Fitzgibbon J (2011) Transformation of indolent B-cell lymphomas. J Clin Oncol 29:1827-1834
2. Lossos IS, Gascoyne RD (2011) Transformation of follicular lymphoma. Best Pract Res Clin Haematol 24:147-163
3. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, Coiffier B (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594 (Pubitemid 27167397)
4. Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539-1545
5. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 26:5165-5169
6. Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, Vinnicombe S, Waters R, Rohatiner AZ, Lister TA (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426-2433 (Pubitemid 47007616)
7. Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PM, Stathis A, Moccia AA, Mazzucchelli L, Bertoni F, Ghielmini M, Cavalli F, Zucca E (2012) Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 157:188-196
8. Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros LJ (2003) Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol 120:246-253 (Pubitemid 37046359)
9. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ (2006) Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24:2343-2351 (Pubitemid 46655600)
10. Koch P, Probst A, Berdel WE, Willich NA, Reinartz G, Brockmann J, Liersch R, del Valle F, Clasen H, Hirt C, Breitsprecher R, Schmits R, Freund M, Fietkau R, Ketterer P, Freitag EM, Hinkelbein M, Heinecke A, Parwaresch R, Tiemann M (2005) Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 23: 7050-7059
11. Yuen AR, Kamel OW, Halpern J, Horning SJ (1995) Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol 13:1726-1733
12. Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88
13. Bernstein SH, Burack WR (2009). The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009(1):532-541
14. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, Group, M.I.T (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391
15. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, (DSHNHL), G.H.-G.N.-H.L.S.G. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116
16. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242 (Pubitemid 34438862)
17. Al-Tourah AJ, Savage KJ, Gill KK, Sehn LH, Shenkier TN, Gascoyne RD, Conners JM (2007) Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood 110: abstr 790
18. Tan D, Rosenberg SA, Levy R, Lavori P, Tibshirani R, Hoppe RH, Warnke R, Avandi R, Natkunam Y, Yuen A, Horning SJ (2007) Survival in follicular lymphoma: the Stanford experience, 1960-2003. Blood 110: abstr 3428
19. Fukuhara S, Maruyama D, Miyamoto K-i, Kim S-W, Watanabe T, Kobayashi Y, Taniguchi H, Maeshima AM, Tobinai K (2012) Clinicopathologic analysis of follicular lymphoma (FL) patients with coexisting diffuse large B-cell lymphoma (DLBCL) undergoing rituximab-containing chemotherapy. Blood 120: abstr 3693
20. Ghesquières H, Berger F, Felman P, Callet-Bauchu E, Bryon PA, Traverse-Glehen A, Thieblemont C, Baseggio L, Michallet AS, Coiffier B, Salles G (2006) Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 24:5234-5241 (Pubitemid 46631367)
21. Hubbard SM, Chabner BA, DeVita VT, Simon R, Berard CW, Jones RB, Garvin AJ, Canellos GP, Osborne CK, Young RC (1982) Histologic progression in non-Hodgkin's lymphoma. Blood 59: 258-264 (Pubitemid 12172012)
22. Oviatt DL, Cousar JB, Collins RD, Flexner JM, Stein RS (1984) Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer 53:1109-1114 (Pubitemid 14196491)
23. Tan D, Rosenberg SA, Lavori P, Hoppe LR, Warnke R, Avandi R, Natkunam Y, Yuen A, Horning SJ (2008) Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): the Stanford experience 1960-2003. Annals of Oncology 19 (suppl 4): abstr 089
24. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42-51
25. Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, Macdonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J (2013) Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. J Clin Oncol 31: 1164-1171